SAB Biotherapeutics (NASDAQ:SABSW – Get Free Report) is anticipated to announce its results before the market opens on Thursday, August 6th. Analysts expect SAB Biotherapeutics to post earnings of ($0.2830) per share and revenue of $0.1250 million for the quarter.
SAB Biotherapeutics Price Performance
Shares of SABSW opened at $0.02 on Tuesday. The business has a 50-day moving average of $0.01 and a 200 day moving average of $0.02. SAB Biotherapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.06.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
See Also
- Five stocks we like better than SAB Biotherapeutics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
